Detalhe da pesquisa
1.
Evasion of NKG2D-mediated cytotoxic immunity by sarbecoviruses.
Cell
; 187(10): 2393-2410.e14, 2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38653235
2.
SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy : An Observational Study.
Ann Intern Med
; 176(12): 1577-1585, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37956428
3.
Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19).
Clin Infect Dis
; 76(3): e526-e529, 2023 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35737946
4.
Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection.
N Engl J Med
; 387(3): 275-277, 2022 07 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35767428
5.
SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency.
Sci Transl Med
; 16(731): eadk1599, 2024 Jan 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38266109
6.
A PSD-95 peptidomimetic mitigates neurological deficits in a mouse model of Angelman syndrome.
Prog Neurobiol
; 230: 102513, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37536482
7.
SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy.
medRxiv
; 2023 Jun 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37425934
8.
SARS-CoV-2 Viral Clearance and Evolution Varies by Extent of Immunodeficiency.
medRxiv
; 2023 Aug 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37577493
9.
Viral Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in mRNA-Vaccinated Individuals Treated and Not Treated with Nirmatrelvir-Ritonavir.
medRxiv
; 2022 Aug 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35982651
10.
Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variant.
JCI Insight
; 7(19)2022 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36214224
11.
Duration of viable virus shedding in SARS-CoV-2 omicron variant infection.
medRxiv
; 2022 Mar 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35262089
12.
Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody Responses.
medRxiv
; 2022 Mar 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35262094
13.
The Effect of a Student Pharmacist Directed Health-Education Program for Elementary-School Children.
Innov Pharm
; 10(4)2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-34007596